Synthesis and Evaluation of Cytotoxic Activity of 3-((1H-Benzo[d]imidazol-2-yl)methyl)-2-phenylquinazolin-4(3H)-one Derivatives on MCF-7 Cell Line

Abstract

Cancers, particularly, breast cancer is one of the deadliest disease in women and requires to be treated with lowest side-effects and toxicity. Quinazolinone and Benzimidazole nucleus are privileged nucleus with reported anti-cancer activity. Hence, combined derivatives of 3-((1H-Benzo[d]imidazol-2-yl)methyl)-2-phenylquinazolin-4(3H)-one E(1-8) were prepared and tested for cytotoxicity on MCF-7 cell line. Compound E6 showed 70.74% inhibition of cell growth as compared to 86.96% inhibition by standard doxorubicin.